Outset Medical wins FDA nod for next-gen Tablo hemodialysis system
January 27, 2026
Outset Medical (Nasdaq: OM)+
announced today that it received FDA 510(k) clearance for its next-generation Tablo hemodialysis platform.
Outset Medical (Nasdaq: OM)+
announced today that it received FDA 510(k) clearance for its next-generation Tablo hemodialysis platform.